Drug intelligence / Profile preview

human papillomavirus type 58 L1 protein virus-like particle

Development stage
Preclinical
Lead developer
Merck
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

Human papillomavirus type 58 L1 protein virus-like particle is a **recombinant HPV58 major capsid protein self-assembled into non-infectious virus-like particles** intended to function as an HPV vaccine antigen. As an L1 VLP vaccine, it is designed to present conformational epitopes that induce **type-specific neutralizing antibody responses against HPV58**, thereby helping prevent infection and HPV58-associated neoplastic disease rather than directly killing infected cells. HPV58 is a high-risk genotype linked to cervical precancer and cancer, with particular epidemiologic importance in East Asia. Based on the name provided and the available context, this entity appears to refer to a **monovalent HPV58 VLP antigen/candidate** rather than an approved commercial product; Institut Gustave Roussy is listed in the provided context as a known developer, and the associated disease context is high-grade squamous intraepithelial lesion related to HPV.

Other names
HPV58 L1 virus-like particleHPV-58 L1 virus-like particleHPV 58 L1 virus-like particlehuman papillomavirus 58 L1 virus-like particlehuman papillomavirus type 58 L1 protein VLP

Beyond the preview

Go deeper on human papillomavirus type 58 L1 protein virus-like particle.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on human papillomavirus type 58 L1 protein virus-like particle.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call